- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Patent holdings for IPC class C07D 215/48
Total number of patents in this class: 507
10-year publication summary
|
30
|
21
|
39
|
33
|
30
|
27
|
30
|
36
|
20
|
17
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Eisai R&D Management Co., Ltd. | 1221 |
34 |
| Exelixis, Inc. | 401 |
14 |
| F. Hoffmann-La Roche AG | 7948 |
10 |
| Pfizer Inc. | 3386 |
10 |
| Taisho Pharmaceutical Co., Ltd. | 865 |
10 |
| Bayer Pharma AG | 1054 |
9 |
| Sumitomo Chemical Company, Limited | 9079 |
8 |
| Astellas Pharma Inc. | 1087 |
8 |
| Lohocla Research Corporation | 16 |
8 |
| Regenacy Pharmaceuticals, LLC | 26 |
7 |
| Merck Sharp & Dohme LLC | 3753 |
7 |
| Glaxosmithkline Intellectual Property (no.2) Limited | 288 |
6 |
| Arcus Biosciences, Inc. | 140 |
6 |
| Waters Technologies Corporation | 1707 |
6 |
| Shanghai AB PharmaTech Ltd. | 6 |
6 |
| Centre National de La Recherche Scientifique | 10564 |
5 |
| Bayer AG | 3356 |
5 |
| ChemoCentryx, Inc. | 383 |
5 |
| Gilead Sciences, Inc. | 2056 |
5 |
| Novartis AG | 10721 |
4 |
| Other owners | 334 |